Promentis Pharmaceuticals to Present at Society for Neuroscience Meeting

Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, announced today that Dr. Chad Beyer, Senior Vice President of R&D, will present at the 47th Annual Society for Neuroscience (SFN) meeting, taking place November 11-15, 2017 in Washington DC.

Dr. Chad Beyer, Senior Vice President of R&D, will present at the 47th Annual Society for Neuroscience (SFN) meeting

Milwaukee, WI – November 10, 2017Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, announced today that Dr. Chad Beyer, Senior Vice President of R&D, will present at the 47th Annual Society for Neuroscience (SFN) meeting, taking place November 11-15, 2017 in Washington DC.

 

This presentation is scheduled for:

Date: Tuesday, November 14, 2017
Poster Presentation Time: 1:00 p.m. – 2:00 p.m. Eastern Time
Poster Number: 610.13 / RR31
Title: SXC-2023: Preclinical Characterization of a Novel Activator of the Cystine Glutamate Antiporter (System xc) and Potential Therapeutic for CNS Disorders

 

For further information, please contact:

Promentis Pharmaceuticals:
Chad E. Beyer, PhD
(e) cbeyer@promentispharma.com 

Media Contact:
Tiberend Strategic Advisors, Inc.
Janine McCargo
(t) 646-604-5150
(e) jmccargo@tiberend.com